OBJECTIVE: This study investigated the prognostic impact of multimodality therapies in locally advanced thymomas. METHODS: From January 1990 to January 2010, clinicopathological, surgical, and oncological features were retrospectively reviewed in a cohort of 370 Masaoka-Koga stage III thymomas (World Health Organization classification A to B3) collected from 37 institutions. A multivariate Cox proportional hazard model was created to identify independent predictors of overall, cancer-specific (CSS), and relapse-free survivals. Furthermore, a propensity score-matching analysis for exposure to adjuvant (AT) therapy was generated. RESULTS: Induction therapy and AT were administered to 88 (24.9%) and 245 (69.4%) patients, respectively. Overall,...
INTRODUCTION: Thymic carcinoma is a rare and aggressive thymic neoplasm. The European Society of Tho...
OBJECTIVES: A retrospective database was developed by the European Society of Thoracic Surgeons, col...
Introduction: The International Thymic Malignancy Interest Group (ITMIG) classifies thymoma recurren...
OBJECTIVE This study investigated the prognostic impact of multimodality therapies in locally advanc...
OBJECTIVE This study investigated the prognostic impact of multimodality therapies in locally advanc...
OBJECTIVE: This study investigated the prognostic impact of multimodality therapies in locally adva...
Objective: We sought to evaluate factors influencing long-term survival of patients with locally adv...
OBJECTIVES: A retrospective database was developed by the European Society of Thoracic Surgeons, col...
IntroductionThis study aimed to evaluate the long-term efficacy of multimodality therapy for patient...
PURPOSE: To assess the role of multimodality treatment on patients with thymic epithelial tumors (TE...
PURPOSE: To assess the role of multimodality treatment on patients with thymic epithelial tumors (TE...
PURPOSE: The optimal therapy for locally advanced malignant thymoma is controversial. We review our ...
Introduction: The International Thymic Malignancy Interest Group (ITMIG) classifies thymoma recurren...
Introduction:To evaluate prognostic factors of thymic epithelial tumors (TETs) with particular refer...
Introduction: Thymic carcinoma is a rare and aggressive thymic neoplasm. The European Society of Tho...
INTRODUCTION: Thymic carcinoma is a rare and aggressive thymic neoplasm. The European Society of Tho...
OBJECTIVES: A retrospective database was developed by the European Society of Thoracic Surgeons, col...
Introduction: The International Thymic Malignancy Interest Group (ITMIG) classifies thymoma recurren...
OBJECTIVE This study investigated the prognostic impact of multimodality therapies in locally advanc...
OBJECTIVE This study investigated the prognostic impact of multimodality therapies in locally advanc...
OBJECTIVE: This study investigated the prognostic impact of multimodality therapies in locally adva...
Objective: We sought to evaluate factors influencing long-term survival of patients with locally adv...
OBJECTIVES: A retrospective database was developed by the European Society of Thoracic Surgeons, col...
IntroductionThis study aimed to evaluate the long-term efficacy of multimodality therapy for patient...
PURPOSE: To assess the role of multimodality treatment on patients with thymic epithelial tumors (TE...
PURPOSE: To assess the role of multimodality treatment on patients with thymic epithelial tumors (TE...
PURPOSE: The optimal therapy for locally advanced malignant thymoma is controversial. We review our ...
Introduction: The International Thymic Malignancy Interest Group (ITMIG) classifies thymoma recurren...
Introduction:To evaluate prognostic factors of thymic epithelial tumors (TETs) with particular refer...
Introduction: Thymic carcinoma is a rare and aggressive thymic neoplasm. The European Society of Tho...
INTRODUCTION: Thymic carcinoma is a rare and aggressive thymic neoplasm. The European Society of Tho...
OBJECTIVES: A retrospective database was developed by the European Society of Thoracic Surgeons, col...
Introduction: The International Thymic Malignancy Interest Group (ITMIG) classifies thymoma recurren...